

A rare case of postsurgical nosocomial infection of Conjunctiva by *Trichosporon* species.

Rajashri Patil¹, Jyoti Ajagunde¹, Sriram Kannuri¹, Sameena Khan¹, Sahjid S Mukhida¹

¹Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India

Corresponding Author

Sahjid S Mukhida

E-mail ID: drssmukhida@rediffmail.com

Submission: 24.10.2022

Acceptance: 23.12.2022

Publication: 31.12.2022

https://www.doi.org/10.56136/BVMJ/2022_00099

Introduction

Trichosporon species are ubiquitous basidiomycete yeast-like fungi that are often part of the human microbiota and responsible for conditions like superficial skin infection (white piedra), allergic pneumonitis, and life-threatening fungal invasive infections in immunocompromised or critically ill patients receiving antibiotics^(1,2). *Trichosporon* invasive infections are considered the second most common cause of fungemia in patients with hematological malignancies^(3,4). In recent years, this genus has been recognized as an emergent pathogen. But therapeutic management of those infections may be challenging, since *Trichosporon* spp. exhibits intrinsic resistance to the Echinocandins and has poor susceptibility to the polyenes⁽²⁾. It can have a high mortality rate even with the treatment of Amphotericin B treatment⁽⁵⁾.

Trichosporonosis is rare in immunocompetent individuals. We report a case of trichosporonosis by *Trichosporon asahii* in an immunocompetent individual to alert the clinicians to avoid life-threatening complications of trichosporonosis.

Patient History

A 28-year-old male, working as a blacksmith presented to the emergency department with a diminution of vision, a burning sensation, and watering in his left eye for two days. The patient gave a history of burn injury to the left eye, which was three days old. After preliminary examination, the patient was admitted and started on an empirical course of antibiotics, and an initial plan for grafting was formulated. The patient underwent an amniotic membrane graft as part of his initial management plan. The site of surgery took up the graft well, and the wound was healthy with no signs of infection. After the initial grafting, a second membrane grafting surgery was planned in conjunction with a reconstruction of the upper and lower eyelid with a flap. The attending physician noted discharge from the surgical site one week after the reconstruction surgery. The patient also had itching, periorbital redness along with ocular discharge. The wound was not healing and did not look healthy. The ophthalmologist suspected endophthalmitis (Figure 1). The discharge was collected using a swab and was sent for microbiological investigations to the department of Microbiology.



Figure 1: Infected eye with discharge

The sample was processed for gram staining and inoculated for culture. On Gram stain, Gram-positive yeast-like structures were seen. The first-day reading of the inoculated Blood Agar and Sabouraud Dextrose Agar (SDA) culture plate did not yield any visible growth. After 48 hours of incubation, dry-off white, medium-sized circular colonies were noted in the blood agar plate. Gram staining of the colony revealed Gram-positive barrel shape yeast cells (Figure 2). The finding was communicated to the treating ophthalmologist, and a repeat sample was requested to rule out the possibility of potential contamination. A repeat specimen was received the next day, and similar growth was also noted in the second sample. Vitek 2 Compact (Biomerux, France) automation system was employed to identify the isolate. The report was intimated to the treating doctor, and the choice of treatment (Ketoconazole/voriconazole) was advised. But the patient was not willing for further management, and he took discharge against medical advice.




Figure 2: Gram stain of *Trichosporon asahii*

Discussion

Trichosporon spp. is a ubiquitous yeast that inhabit the soil, but may also be part of normal human skin and respiratory tract flora⁽⁶⁾. *Trichosporon* spp., formerly known as *Trichosporon beigelii*⁽⁷⁾, includes several genetically distinct species. *Trichosporon* species are increasingly reported and considered to be emerging pathogenic fungi among immunosuppressed patients. The fungus can cause invasive disease at one site or in a disseminated form in which the main targets are the lungs, kidneys, skin, and eyes. Though rare, *T. asahii* can cause invasive infections even in immunocompetent individuals at various sites. In these cases, the infection is associated either with the presence of a foreign body, such as a prosthetic heart valve, an indwelling catheter, or intravenous drug abuse. Other factors like broad-spectrum antibiotic treatment and breaks in the mucosal barrier can enhance mucosal colonization and subsequent invasion of *Trichosporon* species⁽⁸⁾. *Candida* species can identify on the base of growth on CHROMagar (Chromogenic agar)⁽⁹⁾, while *Trichosporon* species cannot. It gives dry, light blue colonies on the CHROMagar while dry white colonies on the SDA agar.

T. asahii is also among the *Trichosporon* species frequently observed in cases of immunocompromised patients^(10,11) and can cause fatal systemic mycosis with mortality rates approaching 80%^(12,13). A case of postsurgical endophthalmitis caused by *T. beigelii* in an immunocompetent patient was reported by Spirm et al. with systemic and ocular sarcoidosis⁽¹⁴⁾. Similarly, our patient did not have any underlying immunocompromised condition, but had a history of burn injury to the eye.

In present case report, anti-fungal susceptibility was not performed for *Trichosporon* species because breakpoints have not been described in Clinical and Laboratory Standards Institute (CLSI) guidelines. Azoles (Ketoconazole, voriconazole) are the preferred treatment for *Trichosporon* spp. and were advised. In many studies of *Trichosporon* spp. antifungal susceptibility, breakpoints of *Candida* spp. have been used for interpretation, and no defined cutoff values or breakpoints have been documented in CLSI and The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Those studies perform the anti-fungal susceptibility testing using old CLSI guidelines 2008. We advise the common antifungal drug for treatment⁽¹⁵⁻¹⁸⁾. More clinical outcome studies using antifungal treatment outcomes should be done. This will help define the necessary breakpoints, helping the treating physicians' better target therapeutic options.

Limitation

The patient took discharge against medical advice due to his personal reason. He did not return for further follow-up and

hence treatment outcome of the present case report was not known. Yet, this case report provides insights to physicians while treating an infected wound.

Conclusion

Most of the time, infected wounds can get over-treated for bacterial infection, but in cases of high index of clinical suspicion, a careful microbiological evaluation for fungal pathogens, even in immunocompetent individuals, should be done for detection of fungal etiology and starting antifungal in early stage. It may help immensely in the prevention of mortality and morbidity and improve the outcome of patients.

Ethical Considerations

Ethical approval was waived off by the Institutional ethical sub-committee for case reports. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Conflict of Interest: Nil

Source of Support: Nil

Copyright © 2022 The Author. This is an open access article, it is free for all to read, download, copy, distribute, adapt and permitted to reuse under Creative Commons Attribution Non Commercial-ShareAlike: CC BY-NC-SABY4.0 license.

References

- Chander J. Ed. Nayak N. Textbook of medical mycology; 4th edition, Jaypee Brothers Medical Publishers, July 2017; pp 155-156.
- de Almeida Júnior JN, Hennequin C. Invasive *Trichosporon* Infection: a Systematic Review on a Re-emerging Fungal Pathogen. *Front Microbiol.* 2016 Oct 17;7:1629. DOI: 10.3389/fmicb.2016.01629.
- Walsh TJ, Newman KR, Moody MA, Wharton RC, Wade JC. *Trichosporon*osis in patients with neoplastic disease. *Medicine (Baltimore).* 1986 Jul 1;65(4):268-79. DOI: 10.1097/00005792-198607000-00005.
- Winn W, Allen S, Janda W, et al. *Koneman's Color Atlas and Textbook of Diagnostic Microbiology.* 6th Edition, Lippincott Williams and Wilkins, New York, 6th edition. 2006 Chapter 21, page 1224-1225.
- Tanyildiz HK, Yesil S, Toprak S, Candir MO, and Sahin G. Two Case Presentations Infected by *Trichosporon asahii* and Treated with Voriconazole Successfully. *Case Reports in Infectious Diseases.* 2015 October. DOI: 10.1155/2015/651315.
- Paphitou N, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of *Trichosporon* species. *Antimicrobial Agents Chemother.* 2002 Apr;46(4):1144-6.

7. Walsh TJ, Hayden RT, Larone DH. Larone's Medically important fungi. 6th edition, pp 163-164.
8. Devi KM, Mate PH, Singh LN, Devi KR, Devi KS. Disseminated infection with *Trichosporon asahii* in an immunocompetent patient: A rare case report. *J Med Soc.* 2015 Sep 1;29(3):174-6.
9. Mukhida S, Mirza S, Vyawahare C, et al. Fungus profile in urinary tract infections in a tertiary care setup. *International J of Healthcare and Biomedical research.* 2021 Apr;9(03):11-6.
10. Woolf DG, Falk R, Hacham M, et al. Multidrug-resistant *Trichosporon asahii* infection of nongranulocytopenic patients in three intensive care units. *J Clin Microbiol.* 2001 Dec 1; 39(12):4420-5.
11. Gonul S, Gedik S, Ozturk BT, et al. Postoperative fungal endophthalmitis caused by *Trichosporon asahii* treated with voriconazole. *Arq Bras Oftalmol.* 2015 Jul-Aug;78(4):252-4. DOI: 10.5935/0004-2749.20150065.
12. Gandham NR, Jadhav SV, Misra RN, Vyawahare CR, Gupta NS. Clinical Significance of Non-Candidal Yeast like Genera with special reference to *Trichosporon* and *Malassezia*. *J. Clin Diagn Res.* 2018 Aug 1;12(8):28-31.
13. Erer B, Galimberti M, Lucarelli G, et al. *Trichosporon beigellii*: A life-threatening pathogen in immunocompromised host. *Bone Marrow Transplant* 2000 Apr;2(7):745-9.
14. Spirn JM, Roth DB, Yarian DL, Green SN. Postoperative fungal endophthalmitis caused by *Trichosporon beigellii* resistant to Amphotericin B. *Retina.* 2003 Jun 1;23(3):404-5.
15. Lemes RM, Lyon JP, Moreira LM, Resende MA. Antifungal susceptibility profile of *Trichosporon* isolates: correlation between CLSI and etest methodologies. *Braz J Microbiol.* 2010 Apr;41(2):310-5. DOI: 10.1590/S1517-83822010000200008. Epub 2010 Jun 1.
16. Mehta V, Nayyar C, Gulati N, Singla N, Rai S, Chandar J. A Comprehensive Review of *Trichosporon* spp.: An Invasive and Emerging Fungus. *Cureus.* 2021 Aug 21;13(8):e17345. DOI: 10.7759/cureus.17345.
17. Guo LN, Yu SY, Hsueh PR, et al. Invasive Infections Due to *Trichosporon*: Species Distribution, Genotyping, and Antifungal Susceptibilities from a Multicenter Study in China. *Journal of clinical microbiology.* 2019 Feb 1;57(2):e01505-18.
18. Francisco EC, de Almeida Jr JN, de Queiroz Telles F, et al. Species distribution and antifungal susceptibility of 358 *Trichosporon* clinical isolates collected in 24 medical centres. *Clinical Microbiology and Infection.* 2019 Jul 1;25(7):909-e1-e5.